CLINICAL GUIDELINE FOR THE TREATMENT OF DIABETIC NEPHROPATHY
https://doi.org/10.20514/2226-6704-2015-0-5-9
Abstract
Due to the high prevalence of diabetes the annual increase of the number of patients with diabetic nephropathy is evidenced. The progressive course of this sequellae and a high percentage of end-stage kidney disease requires a clear approach of early diagnosis, the development of methods of prevention and early treatment from the perspective of evidence-based medicine. This review provides recommendations on glucose-lowering treatment, monitoring of blood pressure and proteinuria, hyperlipidemia. Defi ned individual targets of the correction of hyperglycaemia, depending on the level of albuminuria excretion and the severity of the patient. Indicated the possibilities of applications of certain antidiabetic drugs, depending on the level of glomerular fi ltration rate. Drugs of the fi rst and second line are marked for the selection of antihypertensive treatment. Showed the possible ways to reduce the level of albuminuria. Presented recommendations for the management of patients, depending on the stage of nephropathy.
About the Authors
R. A. Nadeeva
Kazan State Medical University
Russian Federation
Kazan
Russian Federation
Kazan
O. N. Sigitova
Kazan State Medical University
Russian Federation
Kazan
Russian Federation
Kazan
References
1. Algoritmy specializirovannoj medicinskoj pomoshchi bol'nym saharnym diabetom (6-j vypusk) [Algorithms specialized medical care to patients with diabetes]. Working Group to prepare recommendations led Dedov II, Shestakova MV. Diabetes mellitus. 2013;(1S): 1-120.
2. Dedov I.I., Shestakova M.V. Saharnyj diabet: ostrye i hronicheskie oslozhneniya [Diabetes: acute and chronic complications]. Moscow: Medical News Agency, 2011.
3. Shestakova M.V., Dedov I.I. Saharnyj diabet i hronicheskaya bolezn' pochek. [Diabetes mellitus and chronic kidney disease ] Moscow: Medical News Agency, 2009.
4. ADA. Standards of medical care in diabetes―2013. Diabetes Care. 2013;36:S11-66
5. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements 2012; 2, S 335-S 414. http://www.kidney-international.org
6. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intern. Suppl. 2013; (3).
7. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am. J. Kidney Dis. 2012;60(5):850-886.
8. Standards of medical care in diabetes 2014. American Diabetes Association. Diabetes Care 2014; 37(Suppl.1): S14-S80.
9. 2013 ESH/ESC Guidelines for the management of arterial hypertension Eur Heart J 2013; 34: 2159–2219. doi:10.1093/eurheartj/eht151.
10. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcmes in patients with type 2 diabetes. N. Engl. J. Med. 2008 Jun12; 358(24):2560-72.
11. Chalmers J., Joshi R., Kengne A.P., MacMahon S. Blood pressure lowering withfixed combination perindopril-indapamide: key findings from ADVANCE. J Hypertens Suppl. 2008 Jun; 26(2):S11-5..
12. Cost effectiveness analysis of improved blood pressure control inhypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998 Sep12; 317(7160):720-6.
13. Packham D.K., Wolfe R., Reutens A.T. et al. Collaborative Study GroupSulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy. J. Am. Soc. Nephrol. 23: 123–130, 2012
14. Diabetes Control and Complications Trial/Epidemiology of Diabetes interventions and Complications (DCCT/EDIC) Research Group, Nathan D.M., Zinman B., Cleary P.A., Backlund J.Y., Genuth S., Miller R., Orchard T.J. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).Arch Intern Med. 2009 Jul 27; 169(14):1307-16.
15. Douglas K., O'Malley P.G., Jackson J.L. Meta-analysis: the effect of statins on failure. Kidney Int. 2011; 80(5): 516-523.
16. Hallan S.I., Orth S.R. Smoking is a risk factor in the progression to kidney intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12; 352(9131):837-53. Erratum in: Lancet 1999 Aug 14; 354(9178):602.
17. International Diabetes Federation. Global Guideline for Type 2 diabetes. 2012.
18. Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000 Dec9; 321(7274):1440-4.
19. Nathan D.M., Cleary P.A., Backlund J.Y. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med.2005. Dec 22; 353(25):2643-53.
20. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 update. Am J Kidney Dis 2012; 60: 850–886.
21. Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients: The Di.N.A.S. Randomized Trial
22. Predictors of the development of microalbuminuria in patients with Type I diabetes mellitus: a seven-year prospective sudy. The Microalbuminuria Collaborative Study Group. Diabet Med. 1999 Nov; 16(11):918-25.
23. Sarafidis P.A., Stafylas P.C., Georgianos P.I. et al Effect of Tiazolidindiones on albuminuria and proteinuria in diabetes: a metaanalysis. Am J Kidney dis 2010; 55(5): 835-847.
24. Schwartz V. Critical notes on the results of studies (ACCORD, ADVANCE, VADT) of the efficiency of intensive therapy of type 2 diabetes mellitus. Klin Med (Mosk). 2011; 89(3):18-20. Review. Russian.
25. Tight blood pressure control and risk of macrovascular and microvascularcomplications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12; 317(7160):703-13. Erratum in: BMJ 1999 Jan 2; 318(7175):29.
26. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317:703–713, 1998
27. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect ofintensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003 Oct 22; 290(16):2159-67.
Review
For citations:
Nadeeva R.A., Sigitova O.N. CLINICAL GUIDELINE FOR THE TREATMENT OF DIABETIC NEPHROPATHY. The Russian Archives of Internal Medicine. 2015;(5):3-8. (In Russ.) https://doi.org/10.20514/2226-6704-2015-0-5-9
Views:
2140
Email this article 